Our company independently developed a brand new molecular body with global patent protection, the international first subtype of selective histone deacetylase ( HDAC ) oral inhibitor, and the national class 1.1 new drug Chidamide ( Epidaza ? ), which was approved for listing by China Food and Drug Administration (CFDA) on December 23, 2014. Chidamide belongs to a completely new mechanism of action - epigenetic regulator anti-tumor drugs, which CFDA has approved this time to treat patients with relapsed and refractory peripheral T-cell lymphoma. Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous lymphoproliferative disorders with 23 pathological subtypes. The distribution of PTCL subtypes varies in different regions, and PTCL - unspecified type (PTCL - NOS) is the most common type in north America and Europe. In China, the high incidence rate includes extranodal NK/T-cell lymphoma and vascular immune mother cell lymphoma. At present, there is a lack of recommended treatment methods for standard drugs in clinical practice. the response rate to conventional chemotherapy is low and it is easy to relapse. the overall 5 - year survival rate is only 25 - 30 %. There is no special medicine to treat this kind of disease in our country, which is an urgent clinical need. Chidamide and other anti-tumor drugs in the treatment of non-small cell lung cancer and recurrence and metastasis of breast cancer clinical trials are underway. Chidamide, which lasted 12 years from discovery to approval, is a special topic of " major new drug discovery" in the national " 863", " 11th five-year plan" and " 12th five-year plan".